ATARA Biotherapeutics (ATRA) Tops Q1 EPS by 6c

ATARA Biotherapeutics (NASDAQ: ATRA) reported Q1 EPS of ($0.86), $0.06 better than the analyst estimate of ($0.92). Revenue for the quarter came in at $3.55 million versus the consensus estimate of $1.6 million.

For earnings history and earnings-related data on ATARA Biotherapeutics (ATRA) click here.

You May Also Be Interested In

• Greenbrier Cos. (GBX) Reports In-Line Q3 EPS
• NHC acquires 35 facilities from NHI for $560 million
• Biogen expects $164M R&D charge to hit Q2 2026 earnings